Combined therapy for the treatment of executive function disorders
Patent Information
- Authority / Receiving Office
- ES · ES
- Patent Type
- Patents
- Filing Date
- 2022-02-03
- Publication Date
- 2026-07-16
AI Technical Summary
Current treatments for executive function disorders such as ADHD and autism, particularly those using molecular stimulants like methylphenidate, are associated with significant side effects and develop tolerance over time, leading to short-term efficacy without addressing the underlying causes.
A combination therapy of lacosamide and oxcarbazepine, administered in specific dosages, is used to treat executive dysfunction symptoms in a subject in need thereof, wherein the lacosamide is administered to the subject in a combination of lacosamide and oxcarbazepine, administered to the subject in an amount of 100-400 mg/day, and the oxcarbazepine is administered to the subject in an amount of 600-1200 mg/day.
The combination therapy effectively reduces symptoms of executive dysfunction with minimal side effects and provides long-lasting stabilization, improving cognitive function, reducing hyperactivity and impulsivity, and enhancing social skills without developing tolerance.